



(51) International Patent Classification:

<i>A61P 31/14</i> (2006.01)	<i>A61K 9/00</i> (2006.01)
<i>A61K 31/4706</i> (2006.01)	<i>A61K 9/12</i> (2006.01)
<i>A61K 47/10</i> (2017.01)	<i>A61K 9/08</i> (2006.01)

(21) International Application Number:

PCT/EP2021/075136

(22) International Filing Date:

13 September 2021 (13.09.2021)

(25) **Filing Language:** English

English

(26) **Publication Language:** English

English

(30) Priority Data:

20196088.7 14 September 2020 (14.09.2020) EP

(71) Applicant: **PHILIP MORRIS PRODUCTS S.A.**
[CH/CH]: Ouai Jeanrenaud 3, 2000 Neuchâtel (CH).

Inventors: CALVINO, Florian Alexis; Quai Jeanrenaud 3, 2000 Neuchâtel (CH). GUY, Philippe Alexandre; Quai Jeanrenaud 3, 2000 Neuchâtel (CH). HOENG, Julia; Quai Jeanrenaud 3, 2000 Neuchâtel (CH). KOLLI, Aditya Reddy; Quai Jeanrenaud 3, 2000 Neuchâtel (CH). KUCZAJ, Arkadiusz; Quai Jeanrenaud 3, 2000 Neuchâtel (CH). MAJEED, Shoaib; Quai Jeanrenaud 3, 2000 Neuchâtel (CH).

MAZUROV, Anatoly; 3704 Timberoak Dr., Greensboro, Guilford, North Carolina 27410 (US). **PEITSCH, Manuel**; Quai Jeanrenaud 3, 2000 Neuchâtel (CH). **SEMREN, Tanja Zivkovic**; Quai Jeanrenaud 3, 2000 Neuchâtel (CH). **VAN DER TOORN, Marco**; Quai Jeanrenaud 3, 2000 Neuchâtel (CH).

(74) **Agent: ELLIS, Robin;** Reddie & Grose LLP, The White Chapel Building, 10 Whitechapel High Street, Greater London, London Greater London E1 8OS (GB).

(81) Designated States (*unless otherwise indicated, for every*

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SH, SI, SL, ST, SV, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every*

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) **Title:** PHARMACEUTICAL COMPOSITION COMPRISING HYDROXYCHLOROQUINE AND USES THEREOF




Figure 13A




Figure 13B

(57) Abstract: A pharmaceutical composition comprising hydroxychloroquine or a pharmaceutically acceptable salt thereof, and a solvent, wherein the pharmaceutical composition comprises 1 mg/mL to 400 mg/mL hydroxychloroquine or a pharmaceutically acceptable salt thereof, wherein the solvent is selected from propylene glycol, glycerine, propane-1, 3-diol and water or combinations thereof and wherein the pharmaceutical composition is for thermal aerosolization. A pharmaceutical composition comprising hydroxychloroquine or a pharmaceutically acceptable salt thereof for use in the treatment or prevention of a viral lung infection, wherein the pharmaceutical composition is administered by oral inhalation.

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*